Echosens shares a mission with the Fatty Liver Foundation to reach into every community in America to ensure asymptomatic individuals receive the screening and care they need.
Read More
Traditionally a disease that primarily attracted the focused attention of hepatologists, nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, has recently raised alarms across a spectrum of health care providers and payers
A race is under way among pharmaceutical companies to develop drugs that treat a spectrum of liver diseases, including nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and its more severe form, nonalcoholic steatohepatitis (NASH).
A race is under way among pharmaceutical companies to develop drugs that treat a spectrum of liver diseases, including nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and its more severe form, nonalcoholic steatohepatitis (NASH).
After reaching the goal of 100,000 veterans cured of hepatitis C virus (HCV) in as few as two months, the Department of Veterans Affairs (VA) now includes in its contract with Echosens the FibroScan® 430 mini+ portable technology.
Diabetes is one of the leading causes of disability and death in the United States. One in 10 Americans have diabetes — more than 30 million people — and another 84 million adults are at high risk of developing Type 2 diabetes.
Physicians and administrators at some of the nation’s leading Federally Qualified Health Centers (FQHCs) now have the ability to quickly and easily assess liver health to better address the NAFLD epidemic
It’s startling to learn that over 30% of the U.S. population has some degree of non-alcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver and the most common type of liver disease in the Western world
A growing number of healthcare providers are adopting FibroScan, a non-invasive technology to examine patient’s liver at the point of care.
Taking a strong leadership position against the looming worldwide epidemic of liver disease, Echosens is dedicated to the assessment of chronic liver disease and positioned for exponential growth.
